Champions Oncology outlines fiscal 2027 plan with Corellia fully funded as it reports $59.4M revenue and $1.6M adjusted EBITDA (NASDAQ:CSBR)July 27, 2026
Share Facebook Twitter LinkedIn Pinterest Email J. M. Smucker outlines 2–4% net sales growth and $8.50–$9.50 EPS guidance for fiscal 2026 amid Hostess strategy reset and commodity headwinds
Champions Oncology outlines fiscal 2027 plan with Corellia fully funded as it reports $59.4M revenue and $1.6M adjusted EBITDA (NASDAQ:CSBR)July 27, 2026